Ray Therapeutics’ gene therapy is independent of the causative genes driving inherited vision disorders, which CEO Paul Bresge says is important for reaching a broad patient population.

The writing has been on the wall for years: the shift away from fee for service to value-based pay is coming. Recently that message, now in bold type, proliferated to every healthcare media outlet ...